• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • US
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Products
    • US Products By Brand
    • Patient Assistance
    • Product Portfolio
    • Our Process
    • Therapeutic Areas
    • Product Related Issues
  • About Us
    • Novartis US at a Glance
    • Who We Are
    • Diversity and Inclusion
    • Our Leadership
    • Supplier Diversity
    • Research
    • Contact Us
  • Corporate Responsibility
    • Novartis in Society US Reports
    • Corporate Citizenship
    • Business Conduct
    • Corporate Integrity Agreement
    • Payments to HCPs & HCOs
    • Post-Marketing Commitments
    • Enhanced Verification Request
  • News
    • News Archive
    • Statements
    • Stories
    • US Media Contacts
    • Novartis US COVID-19 Initiatives
  • Careers
    • Careers Search
    • Working at Novartis
    • Employee Benefits
    • Awards & Recognition
    • NIBR Careers Frequently Asked Questions
Search
Rob Kowalski, Executive Vice President Head, Regulatory Affairs, Novartis, and US Head of Global Drug Development

Rob Kowalski

Executive Vice President, Head, Regulatory Affairs, Novartis, and US Head of Global Drug Development

  • LinkedIn

Rob Kowalski is Executive Vice President and Head of Regulatory Affairs for Novartis and US Head of Global Drug Development. He serves on the US Country leadership team. Rob and his teams have successfully developed and registered over 100 new chemical entities, new indications, and devices across a wide array of therapeutic areas in the small molecule, biologics, biosimilar, and cell and gene therapy spaces.

Rob previously served as the Global Head of Development Medical Affairs for Novartis. Prior to that, he held regulatory leadership roles at Pharmacia (now Pfizer) and Schering-Plough (now Merck).

Rob is past Chair of PhRMA’s Regulatory Affairs Committee and Vice Chairman of the Board of Directors for the R&D Council of New Jersey. He was a member of the U.S. Food and Drug Administration (FDA) Rare Disease Advisory Panel and an industry representative for both PDUFA V and VI FDA reauthorization negotiations. He is also a member of the Industry Pharmacists Organization Advisory Board and a past member of The Organization for Professionals in Regulatory Affairs Advisory Council.

Rob received a B.S. in Pharmaceutical Sciences and a Ph.D. in Pharmacy, both from the University of Wisconsin, Madison. He completed post-doctoral training at Rutgers University/Sandoz Pharmaceuticals and has trained at the Executive Forum of the Harvard Business School.

    • Share
      • Email
    • Jump to Comments
  • Print
  • Save

You are here

  1. Home ›
  2. About Us ›
  3. Our Leadership ›
  4. US Country Leadership

Novartis United States

  • Our Products
  • About Us
  • News
  • Careers
  • Contact Us
  • Corporate Responsibility
  • Locations

Subscribe to Novartis

  • Facebook
  • Twitter
  • YouTube
  • LinkedIn
  • Instagram
  • Novartis Site Directory
© 2021 Novartis Pharmaceuticals Corporation

This site is intended for US Residents Only

  • Terms of Use
  • Privacy Policy
  • About Cookies